| Morphological and cytogenetic characterization and N-myc oncogene analysis of a newly established neuroblastoma cell line. | neuroblastoma, |
| Amplification of c-myc and cyclin D1 genes in primary and metastatic carcinomas of the liver. | liver, |
| Amplification of the c-myc proto-oncogene occurs in hepatocellular carcinoma(HCC) and colorectal adenocarcinoma(MCA); its detection may have a useful diagnostic significance in differentiating intrahepatic cholangiocarcinoma(ICC)from MCA or HCC from ICC. | colorectal,liver,cholangiocarcinoma, |
| Increased expression of the proto-oncogene, c-myc, in human neuroblastoma cells by reversible inhibition of cell growth. | neuroblastoma, |
| Flow cytometric and immunohistochemical analysis of p62c-myc oncoprotein in the bronchial epithelium of lung cancer patients. | lung, |
| Premalignant cervical lesions are characterized by dihydrofolate reductase gene amplification and c-Myc overexpression: possible biomarkers. | cervical, |
| Immunohistochemical analysis of the expression of the c-myc oncoprotein in human stomach cancers. | gastric, |
| The established renal cell carcinoma consist of two cell populations, one containing four and one containing five copies of the MYC oncogene. | kidney, |
| The prognostic value of c-myc oncoprotein levels in malignant melanoma. | skin, |
| Significance of HER2 and C-MYC oncogene amplifications in breast cancer in atomic bomb survivors: associations with radiation exposure and histologic grade. | breast, |
| The c-myc oncoprotein forms a specific complex with the product of the retinoblastoma gene. | retinoblastoma, |
| Establishment and characterization of human signet ring cell gastric carcinoma cell lines with amplification of the c-myc oncogene. | gastric, |
| FRAT1 overexpression leads to aberrant activation of beta-catenin/TCF pathway in esophageal squamous cell carcinoma. | esophageal, |
| in patients with chronic myeloid leukemia, The expression of c-myc (c-myc proto-oncogene) was most pronounced in the Acute phase and then tended to decline | leukemia, |
| Upregulation of nuclear MYC protein expression is a highly prevalent and early change in prostate cancer; increased nuclear MYC may be a critical oncogenic event driving human prostate cancer initiation and progression. | prostate, |
| [Inhibition of proliferation in MCF-7 breast cancer cells by plasmid-based siRNA targeting to oncogene c-myc]. | breast, |
| Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas. | lymphoma,leukemia, |
| The role of the MYC protooncogene in clear cell renal cell carcinoma. | kidney, |
| In the present review, we focus on the deregulation of the MYC oncogene in gastric adenocarcinoma carcinogenesis, including its association with Helicobacter pylori (H pylori) and clinical applications [review] | gastric, |
| MYC and gastric adenocarcinoma carcinogenesis. | gastric, |